

CORRECTION

Open Access



# Correction to: The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study

Ruth E. Costello<sup>1</sup>, Antonia Marsden<sup>2</sup>, Mohammad Movahedi<sup>1,3</sup>, Mark Lunt<sup>1</sup>, Jenny H. Humphreys<sup>1</sup>, Richard Emsley<sup>4</sup> and William G. Dixon<sup>1\*</sup>

**Correction to: BMC Rheumatol 4, 4 (2020)**  
<https://doi.org/10.1186/s41927-019-0105-4>

Following publication of the original article [1], the authors noted several errors in the reported values in Table 2, the 'Results' section of the abstract, and in the first sentence of the "All-cause mortality" sub-section. The correct Table and text are given below with the corrected values highlighted in bold for the Abstract.

The original article has been updated.

## Abstract

**Results:** In those without DM GC use had a 4.4-fold increased all-cause mortality RR (95% confidence interval (CI): **3.77 to 5.07**) compared to non-use, whilst those with DM had a lower RR for GC use (**2.99 (95% CI: 2.32, 3.87)**). However, those with DM had a higher RD associated with GC use because of their higher baseline risk. In those with DM, GC use was associated with an additional **44.9** deaths/1000 person-years (pyrs) (95% CI: **32.9 to 56.8**) compared to non-use, while in those without DM GC use was associated with an additional **34.4** deaths/1000 pyrs (95% CI: **30.1 to 38.7**). A similar pattern was seen for CV mortality. The adjusted Cox proportional hazards model showed no evidence of multiplicative

interaction, but additive interaction indicated a non-significant increased risk. For CV mortality there was no interaction on either scale.

In the "All-cause mortality" sub-section it now correctly reads "During follow-up there were 1005 deaths" rather than 1002 deaths.

## Author details

<sup>1</sup>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. <sup>2</sup>Centre for Biostatistics, School of Health Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. <sup>3</sup>Ontario Best Practices Research Initiative, University Health Network, Toronto, Ontario, Canada. <sup>4</sup>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Published online: 02 March 2021

## Reference

1. Costello RE, Marsden A, Movahedi M, et al. The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study. *BMC Rheumatol.* 2020;4:4. <https://doi.org/10.1186/s41927-019-0105-4>.

The original article can be found online at <https://doi.org/10.1186/s41927-019-0105-4>.

\* Correspondence: [will.dixon@manchester.ac.uk](mailto:will.dixon@manchester.ac.uk)

<sup>1</sup>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK  
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 2** Mortality rates, rate ratios and rate difference by diabetes mellitus and glucocorticoid use status

Outcome		✓RA		✓RA		✓RA		✓RA	
		✓DM ✓GC	*DM *GC	✓DM ✓GC	*DM *GC	✓DM ✓GC	*DM *GC	✓DM ✓GC	*DM *GC
All-cause mortality	Number of events	140		112		442		311	
	Follow-up time	2077.5		4975.3		9914.0		30463.4	
	IR per 1000 person-years (95% confidence interval (CI))	67.4 (57.1 to 79.5)		22.5 (18.7 to 27.1)		44.6 (40.6 to 48.9)		10.2 (9.1 to 11.4)	
	Rate ratio (95% CI)	2.99 (2.32 to 3.87)				4.37 (3.77 to 5.07)			
	Rate difference, per 1000 person-years (95% CI)	44.9 (32.9 to 56.8)				34.4 (30.1 to 38.7)			
CV mortality	Number of events	46		48		150		140	
	Follow-up time	2077.5		4975.3		9920.7		30497.3	
	IR, per 1000 person-years. (95% CI)	22.14 (16.6 to 29.6)		9.65 (7.3 to 12.8)		15.1 (12.9 to 17.7)		4.6 (3.9 to 5.4)	
	Rate ratio	2.30 (1.50, 3.51)				3.29 (2.60 to 4.18)			
	Rate difference (per 1000 person-years )	12.49 (5.54, 19.45)				10.53 (7.99 to 13.07)			